Get the Stockscreener App
204.51
2.16%
-4.51
After Hours:
204.51
Insmed Inc stock is traded at $204.51, with a volume of 2.04M.
It is down -2.16% in the last 24 hours and up +28.09% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$209.02
Open:
$208.49
24h Volume:
2.04M
Relative Volume:
0.87
Market Cap:
$43.62B
Revenue:
$447.02M
Net Income/Loss:
$-1.18B
P/E Ratio:
-33.09
EPS:
-6.1812
Net Cash Flow:
$-906.14M
1W Performance:
+0.47%
1M Performance:
+28.09%
6M Performance:
+202.84%
1Y Performance:
+170.23%
1-Day Range:
$202.27
$209.00
1-Week Range:
$194.65
$209.77
52-Week Range:
$60.40
$209.77
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Targets Report: How Insmed Incorporated (IM8N) stock correlates with oil markets2025 Biggest Moves & Technical Entry and Exit Tips - BỘ NỘI VỤ
Does Insmed Incorporated stock trade at a discount to peers2025 Short Interest & Low Drawdown Trading Strategies - BỘ NỘI VỤ
Insider Sell: Elizabeth Anderson Sells 5,000 Shares of Insmed In - GuruFocus
Is EU Approval of First NCFB Therapy Reframing Insmed’s (INSM) Investment Outlook? - Yahoo Finance
Insmed (INSM) Rose Following Drug Approval - Finviz
What Catalysts Are Shaping the New Narrative for Insmed? - Yahoo Finance
Insmed stock hits 52-week high at 208.14 USD By Investing.com - Investing.com Canada
Insmed stock hits 52-week high at 208.14 USD - Investing.com India
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri - MSN
Trend analysis for Insmed Incorporated this week2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
INSM: TD Cowen Raises Price Target, Maintains Buy Rating | INSM Stock News - GuruFocus
How Insmed Incorporated (IM8N) stock performs in easing cyclesRate Hike & Daily Stock Trend Reports - newser.com
Will Insmed Incorporated (IM8N) stock recover faster than industryFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Insmed wins first EU approval for non-cystic fibrosis bronchiectasis treatment - MarketScreener
Why Insmed Incorporated (IM8N) stock is listed among top recommendationsPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Will Insmed Incorporated stock benefit from automationIndex Update & Accurate Entry/Exit Alerts - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Insider Sell: Leo Lee Sells 75,000 Shares of Insmed Inc (INSM) - GuruFocus
Building trade automation scripts for Insmed IncorporatedCPI Data & Proven Capital Preservation Methods - newser.com
Insmed director Anderson sells $1.96 million in stock By Investing.com - Investing.com South Africa
Insmed director Anderson sells $1.96 million in stock - Investing.com
Insmed Says European Commission Approves Brinsupri for Treatment of Non-Cystic Fibrosis Bronchiectasis - MarketScreener
Peering Into Insmed Inc's Recent Short Interest - Benzinga
Insmed (INSM) Gains EU Approval for First NCFB Treatment - GuruFocus
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union - PR Newswire
Insmed (Nasdaq: INSM) BRINSUPRI Wins EU OK After 19.4% NCFB Exacerbation Reduction - Stock Titan
European Commission Approves Insmed's Chronic Lung Disease Treatment - MarketScreener
Insmed at Jefferies London: Transforming into a Multi-Franchise Entity By Investing.com - Investing.com Nigeria
Insmed at Jefferies London: Transforming into a Multi-Franchise Entity - Investing.com
INSM: Brensocatib and TPIP advances fuel growth, with major data and market expansions ahead - TradingView
Transcript : Insmed Incorporated Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08 - MarketScreener
Here’s What Lifted Insmed Incorporated (INSM) in Q3 - Yahoo Finance
Insmed (INSM) Price Target Increased by 15.76% to 206.22 - Nasdaq
How Insmed Incorporated (IM8N) stock compares with tech leadersJuly 2025 Action & Risk Controlled Stock Alerts - newser.com
Insmed (BIT:1INSM) Price Target Increased by 19.33% to 179.30 - Nasdaq
What drives Insmed Incorporated stock priceEconomic Impact on Stocks & Follow Top Performers in the Community - earlytimes.in
A Fresh Look at Insmed (INSM) Valuation After Recent Share Price Surge - Yahoo Finance
Insmed stock reaches 52-week high at 197.1 USD By Investing.com - Investing.com Nigeria
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.63%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):